{"id":4343,"date":"2025-10-07T16:59:11","date_gmt":"2025-10-07T13:59:11","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=4343"},"modified":"2025-10-11T10:21:09","modified_gmt":"2025-10-11T07:21:09","slug":"plazma-kaynakli-tedaviler-hayat-kurtariyor","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=4343","title":{"rendered":"Plazma Kaynakl\u0131 Tedaviler Hayat Kurtar\u0131yor"},"content":{"rendered":"\n

Plazma kaynakl\u0131 tedaviler, ba\u015fka bir alternatif tedavi se\u00e7ene\u011fi bulunmayan bir\u00e7ok hasta i\u00e7in ya\u015fam boyu s\u00fcren ve hayati \u00f6nem ta\u015f\u0131yan tedavilerin temelini olu\u015fturuyor. Bu y\u0131l 6-10 Ekim tarihleri aras\u0131nda t\u00fcm d\u00fcnyada kutlanan Uluslararas\u0131 Plazma Fark\u0131ndal\u0131k Haftas\u0131 (IPAW) kapsam\u0131nda Takeda T\u00fcrkiye, plazman\u0131n nadir ve karma\u015f\u0131k hastal\u0131klar\u0131n tedavisindeki kritik rol\u00fcne \u00a0dikkat \u00e7ekiyor.<\/strong><\/p>\n\n\n\n

\u201cDaha Sa\u011fl\u0131kl\u0131, Daha Parlak Bir Gelecek\u201d misyonuyla hastalar\u0131n\u0131n ya\u015fam kalitesini art\u0131rmak i\u00e7in yenilik\u00e7i tedaviler geli\u015ftiren Takeda bug\u00fcn 80\u2019den fazla \u00fclkede 50 bini a\u015fk\u0131n \u00e7al\u0131\u015fan\u0131yla Gastroenteroloji, Hematoloji, \u0130mm\u00fcnoloji, Nadir Genetik Hastal\u0131klar, N\u00f6robilim, Onkoloji, Plazma Kaynakl\u0131 Tedaviler ve A\u015f\u0131 alanlar\u0131nda faaliyet g\u00f6steriyor. 244 y\u0131ll\u0131k k\u00f6kl\u00fc ge\u00e7mi\u015finin son 80 y\u0131l\u0131nda uzmanla\u015ft\u0131\u011f\u0131 bu alanlar\u0131n yan\u0131nda, plazma kaynakl\u0131 tedavilerde de \u00f6nemli at\u0131l\u0131mlar yaparak k\u00fcresel deneyimi ve liderli\u011fiyle, plazman\u0131n d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc g\u00fcc\u00fcn\u00fc en ileri teknolojilerle bir araya getiriyor ve bu alanda da hastalar i\u00e7in yenilik\u00e7i tedaviler sunuyor.<\/p>\n\n\n\n

K\u0131rm\u0131z\u0131 kan h\u00fccreleri, beyaz kan h\u00fccreleri ve trombositler \u00e7\u0131kar\u0131ld\u0131ktan sonra kalan kan\u0131n berrak, saman renkli s\u0131v\u0131 k\u0131sm\u0131 olan plazma, y\u00fczy\u0131l\u0131 a\u015fk\u0131n s\u00fcredir nadir, karma\u015f\u0131k hastal\u0131klar i\u00e7in hayati \u00f6nem ta\u015f\u0131yan bir tedavi olarak kullan\u0131l\u0131yor. \u0130nsan v\u00fccudunun enfeksiyonlarla sava\u015fabilmesi i\u00e7in gerekli antikorlar ve kanamalar\u0131 \u00a0durdurabilmesi i\u00e7in gerekli p\u0131ht\u0131la\u015fma fakt\u00f6rleri gibi kritik i\u015flevlere sahip plazma proteinlerinin yetersizli\u011fi, ya\u015fam\u0131 tehdit eden t\u0131bbi durumlara neden oluyor.<\/p>\n\n\n\n

Takeda, plazmaya olan bu ihtiyac\u0131 kar\u015f\u0131lamak i\u00e7in kademeli iyile\u015ftirmelerle yetinmeyip, plazmay\u0131 yeniden hayal ederek \u00e7ok daha geni\u015f ve s\u00fcrd\u00fcr\u00fclebilir \u00e7\u00f6z\u00fcmler geli\u015ftiriyor. Takeda\u2019n\u0131n d\u00fcnya \u00e7ap\u0131ndaki plazma ba\u011f\u0131\u015f a\u011f\u0131n\u0131 olu\u015fturan BioLife Plazma Hizmetleri, ABD ve Avrupa\u2019da 260\u2019tan fazla y\u00fcksek teknolojideki tesiste faaliyet g\u00f6steriyor. D\u00fcnya standartlar\u0131nda ba\u011f\u0131\u015f g\u00fcvenli\u011fi ile y\u00fcksek kalitedeki merkezlerinde, plazma ba\u011f\u0131\u015f\u0131 ile ya\u015fam kurtarmaya ve iyile\u015ftirme s\u00fcrecine katk\u0131 sunma f\u0131rsat\u0131 veriyor.<\/p>\n\n\n\n

Kaynak plazma toplama konusunda k\u00fcresel bilinci art\u0131rmak, plazma protein tedavileri ve nadir hastal\u0131klar hakk\u0131ndaki anlay\u0131\u015f\u0131 art\u0131rmak amac\u0131yla her y\u0131l Ekim ay\u0131n\u0131n ilk haftas\u0131nda d\u00fczenlenen Uluslararas\u0131 Plazma Fark\u0131ndal\u0131k Haftas\u0131 (IPAW) ile ilgili a\u00e7\u0131klamada bulunan Takeda T\u00fcrkiye Medikal Direkt\u00f6r\u00fc Dr. Mahir Kula<\/strong> \u015funlar\u0131 s\u00f6yledi:<\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

\u201c Son 20 y\u0131lda, daha fazla nadir hastal\u0131\u011f\u0131n te\u015fhis edilmesi, hasta say\u0131s\u0131n\u0131n artmas\u0131, bak\u0131m standartlar\u0131n\u0131n y\u00fckselmesi ve tedaviye eri\u015fim imk\u00e2nlar\u0131n\u0131n geni\u015flemesi nedeniyle plazmadan elde edilen tedavilere olan k\u00fcresel talep h\u0131zla art\u0131yor<\/em><\/strong>.3<\/sup><\/em><\/p>\n\n\n\n

Bu ba\u011flamda<\/em><\/strong> <\/em>IPAW; 2013 y\u0131l\u0131ndan bu yana Plazma Protein Tedavileri Derne\u011fi (PPTA) ve \u00fcye \u015firketlerinin, plazma ba\u011f\u0131\u015f\u0131n\u0131n \u00f6nemine y\u00f6nelik fark\u0131ndal\u0131\u011f\u0131 art\u0131rmak i\u00e7in y\u00fcr\u00fctt\u00fckleri koordineli ve ortak bir giri\u015fim olarak hayata ge\u00e7iyor.<\/em><\/strong><\/p>\n\n\n\n

Biz de Takeda olarak, plazma alan\u0131nda b\u00fct\u00fcnc\u00fcl bir yakla\u015f\u0131m benimsiyor, sekt\u00f6r standartlar\u0131n\u0131 yeniden \u015fekillendirirken verimlili\u011fi en \u00fcst d\u00fczeye \u00e7\u0131karmak i\u00e7in \u00e7al\u0131\u015f\u0131yoruz. Bilimsel geli\u015fmelerin yan\u0131 s\u0131ra veri ve teknolojinin g\u00fcc\u00fcnden yararlanarak u\u00e7tan uca inovasyon oda\u011f\u0131nda s\u00fcrd\u00fcr\u00fclebilir b\u00fcy\u00fcmeyi destekliyor, plazma kaynakl\u0131 tedaviler ile hastalara yenilik\u00e7i ve etkili tedavi se\u00e7enekleri sunuyoruz.\u201d<\/em><\/strong><\/p>\n\n\n\n

\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Plazma kaynakl\u0131 tedaviler, ba\u015fka bir alternatif tedavi se\u00e7ene\u011fi bulunmayan bir\u00e7ok hasta i\u00e7in ya\u015fam boyu s\u00fcren ve hayati \u00f6nem ta\u015f\u0131yan tedavilerin temelini olu\u015fturuyor. Bu y\u0131l 6-10 Ekim tarihleri aras\u0131nda t\u00fcm d\u00fcnyada kutlanan Uluslararas\u0131 Plazma Fark\u0131ndal\u0131k Haftas\u0131 (IPAW)[1] kapsam\u0131nda Takeda T\u00fcrkiye, plazman\u0131n nadir ve karma\u015f\u0131k hastal\u0131klar\u0131n tedavisindeki kritik rol\u00fcne \u00a0dikkat \u00e7ekiyor<\/p>\n","protected":false},"author":1,"featured_media":4345,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,42],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4343"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4343"}],"version-history":[{"count":2,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4343\/revisions"}],"predecessor-version":[{"id":4347,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4343\/revisions\/4347"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4345"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}